(
On Wednesday 16 June, the first 4 healthy volunteer patients enrolled on the landmark clinical trial of PreciseInhale®. In total 12 patients will take part. The study aims to be finalized before the end of 2021. The study is being run by
Successful clinical validation would make PreciseInhale® the first aerosol generation platform that could be used from the drug discovery phase, through preclinical studies, all the way to phase I clinical trials in humans. This could significantly reduce translational errors between research stages, reducing risk, costs and accelerating drug development.
ISAB CEO Manoush Masarrat: "The clinical validation of PreciseInhale® will potentially open up new markets valued in the billions of SEK. It would significantly reduce drug development time for pharmaceutical companies, making PreciseInhale® the leading low-risk aerosol delivery system on the market."
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About
https://news.cision.com/inhalation-sciences/r/inhalation-sciences--first-patient-enrolled-in-clinical-trial-of-preciseinhale,c3368468
https://mb.cision.com/Main/15842/3368468/1432841.pdf
(c) 2021 Cision. All rights reserved., source